Brexanolone as an injection for intravenous infusion is in clinical development for women with moderate and severe postpartum depression (PPD). PPD is a mood disorder that can
affect women after childbirth. Women with PPD experience feelings of extreme sadness, anxiety, and exhaustion that may make it difficult for them to complete daily care activities
for themselves or for others. After childbirth, the levels of certain hormones in a woman’s body quickly drops, leading to chemical changes in areas of the brain that regulates mood.
Current treatment of PPD with existing medications such as antidepressants do not address the underlying chemical changes, often resulting in treatment failures.
Brexanolone is an active product of the female reproductive hormone progesterone that regulates a specific neurotransmitter involved in a range of behaviours, including the stress
response. Some small studies have shown that brexanolone rapidly and significantly improves the symptoms of PPD and other hormonal mood disorders when compared to
other treatments. If licensed brexanolone would be the first PPD treatment that specifically targets the underlying disease process in PPD.
Evzio is being developed as an injectable device that contains naloxone, a drug used to reverse the effects of opioid drug overdose. It is designed to be easily administered by non-health professionals in a non-clinical setting. If licensed it has the potential to improve emergency responses to opioid overdoses as it can be used in the home environment, enabling caregivers to respond quickly and confidently due to the voice and visual guidance provided with the device.